FDA Says GlaxoSmithKline’s Advair 500/50 “Not Approvable” For COPD
Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.
Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.